Prosecution Insights
Last updated: November 04, 2026

Primo Biotechnology Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Primo Biotechnology Co. Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is handled by 1 distinct examiner and 1 distinct art unit, indicating a very narrow and specific engagement with the patent office. The limited scope of the data suggests that the company's current legal efforts are directed toward a single specific application. Practitioners should observe that the 1 distinct art unit involved provides a consistent environment for the current prosecution effort.

The busiest examiner for this portfolio is ROGERS, JAMES WILLIAM, who is responsible for 1 busiest examiner pending office action. This matches the total of 1 pending office action for the entire portfolio, signifying that this examiner is the only official currently reviewing the company's work. The use of 1 distinct examiner further centralizes the administrative process. Practitioners should recognize that the 1 busiest examiner pending office action is the sole active item in the portfolio, making the relationship with this specific examiner the primary focus of current prosecution efforts.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROGERS, JAMES WILLIAM 1 46.3% +22.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18054149 Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis ROGERS, JAMES WILLIAM 43d overdue

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18054149 Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis ROGERS, JAMES WILLIAM 43d overdue

Top Art Units

Art UnitApps
1618 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18054149 Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis ROGERS, JAMES WILLIAM 1618 §102§103§112 Non-Final OA 43d overdue Pending Nov 10, 2022

Managing Primo Biotechnology Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Primo Biotechnology Co. Ltd. have?

Primo Biotechnology Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Primo Biotechnology Co. Ltd. applications?

James William Rogers has the most, with 1 of Primo Biotechnology Co. Ltd.'s pending office actions.

What technology area are Primo Biotechnology Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month